INTRODUCTION
The introduction of programmable nucleases such as CRISPR/Cas9 in the arsenal of geneticists trying to edit the human genome has clearly generated great hope of correcting the defects associated with several hereditary diseases. [1] [2] [3] In spite of the great potential of this approach, some structural abnormalities involving large chromosome sections remain difficult to amend. These include large inversions, deletions or duplications, complex chromosomal rearrangements, and aneuploidies. 4 CRISPR/Cas9 has been tested even in some of these large abnormalities, 5 but the results achieved are still unsatisfactory. Indeed, the approach undertaken in Duchenne muscular dystrophy (DMD) animal models and patients, 80% of whom have large deletions, focused on the production of in-frame, albeit abnormal, transcripts by exon skipping, thus coding for an internally deleted protein, which is only partially functional. [6] [7] [8] [9] [10] [11] [12] Likewise, the mutation in fragile X patients is due to an abnormal expansion of triplets in the Xq28 region, which cannot be completely restored by canonical approaches. [13] [14] [15] [16] In addition, aneuploidies involving sex chromosomes are not manageable with any of these methods.
In previous work, we have introduced the concept of chromosome transplantation (CT) as a means to achieve correction in the selected cases that cannot benefit by classical gene therapy methods. 17 CT refers to the precise substitution of an endogenous defective chromosome with a normal exogenous one. CT generates euploid cells and is different from chromosome transfer in which the addition of one or a few chromosomes gives rise to aneuploid cells, which cannot be of clinical utility. Likewise, CT is different from human artificial chromosome (HAC) transfer, in which an artificial vector is added. CT is a new approach that is potentially useful in the new field of "genomic or chromosome therapy," 18 an area that has been long neglected. We showed the feasibility of this approach in mice by performing CT in Hprt-deficient embryonic stem cells (ESCs), 17 a model for the human Lesch-Nyhan (LN) disease, and in induced pluripotent stem cells (iPSCs) from a mouse model of chronic granulomatous disease (CGD). 19 However, to our knowledge, human pluripotent stem cells have so far been refractory to CT, although recently an artificial chromosome has been successfully transferred to human iPSCs. 20 In this study, we report the achievement for the first time of CT in human iPSCs using as proof of concept reprogrammed cells from a LN patient carrying a mutation in the X-linked HPRT gene useful for the selection of the corrected cells. By inactivation of the HPRT gene in patient-derived iPSCs, this approach could be used for the correction of several X-linked disorders.
cells die in hypoxanthine-aminopterin-thymidine (HAT) medium, whereas only the corrected HPRT + cells survive ( Figure 1A ). 
Generation of LN-iPSCs
Fibroblasts from a male LN patient (46,XY), carrying a deletion of the HPRT exon 1, which was confirmed by PCR analysis ( Figure S1A ), were reprogrammed 21 and LN-iPSC clones were identified and characterized. The clones showed an iPSC-like colony morphology, a normal 46,XY karyotype, and stemness markers and were able to differentiate in vitro, as shown by positivity to all three germ-layer markers ( Figures S1B-S1D ). Clone LN-iPSC #1 was chosen for CT experiments.
X. Chromosome Transfer
We initially performed several trials of the classical protocol of chromosome transfer by microcell-mediated chromosome transfer (MMCT) without success. Therefore, we tried several modifications, including a strategy recently reported by us for mouse pluripotent cells, 22 which was adapted to human iPSC lines. With this approach, we were able to obtain several clones in different cell fusion experiments. We report this achievement in detail below.
MMCT requires donor cells able to generate microcells with high efficiency. Not all cell lines have this peculiarity, and the most suitable ones are mouse fibroblast-derived A9 and Chinese hamster ovary (CHO) cells. 23 We initially generated a hybrid A9 mouse cell line (A9/human) containing several human chromosomes, including the X one (Homo sapiens X chromosome [HSAX]), which was used for the initial trials of classical MMCT. However, we were unable to obtain stable clones acquiring the exogenous X chromosome. For this reason, we decided to adapt a strategy recently described by us (retro-MMCT), which exploits the fusogenic properties of the R peptide-deleted envelope (Env) protein (EnvDR) from the amphotropic murine leukemia virus (MLV). 22 In order to use this system, it is important to take into consideration some aspects. The Env protein here exploited is fusogenic for human and mouse cells since they express the receptor for the Env protein; hence, after Env infection, human or mouse cells fuse with each other, forming syncytia. For this reason, we could not use our previously generated donor A9/human cell line for retro-MMCT. We investigated a system to generate a non-auto-fusogenic donor cell line containing the desired HSAX to transplant. To do this, we chose an Hprt To correct the LN-iPSCs by CT, we first transferred a normal HSAX into LN-iPSCs by retro-MMCT. Microcells were prepared from CHO/HSAX cells expressing the EnvDR and then co-cultured with LN-iPSCs. In order to maximize the generation of single-chromosome microcells, the preparation was filtered twice. HSAX transferred LN-iPSC clones were selected in 1Â HAT medium. In the first five successful experiments, 12 clones initially survived (protocol A).
Considering that human iPSCs are more difficult to manipulate than mouse cells, in subsequent experiments (protocol B), we slightly modified some conditions ( Figure 1D ). Essentially, we increased the fusion ratio between microcells and recipient cells from 1:1 to 20:1 to improve the fusion rate, and we reduced the HAT concentration to 0.1Â to minimize the cell suffering under selection. We obtained a higher number of HAT-resistant clones (41 and 27, respectively), representing a chromosome transfer efficiency on the order of 10
À4
clones per recipient cell, comparable to other mouse cell lines previously tested 22 ( Figure 1E ). 2D ). The third clone (LNX-D) stably maintained all three sex chromosomes, but after a few passages in culture it started to differentiate spontaneously, even in selective culture medium. For this reason, the clone underwent a second turn of reprogramming with Sendai virus. After reprogramming, the 47,XXY clone, renamed LNX-D1, started to lose one X chromosome and after six passages (from p4 to p10), and 23% of cells showed a normal 46,XY karyotype ( Figures 3A and 3B ). From this pool, after subcloning, we isolated two subclones (LNX-D1B and LNX-D1T) with a homogeneous corrected 46,XY cell population ( Figure 3C ).
Informative SNP analysis of the parental 47,XXY (LNX-D1) and the two 46,XY CT clones confirmed that the remaining X chromosome was of donor origin ( Figure 4A ).
The three CT clones maintained their pluripotency features, as shown by the expression of stemness markers ( Figure S3A ) and the capacity to form embryoid bodies (EBs) and differentiate into the three germ layers ( Figure S3B ). Although the fusion procedure is not expected to be mutagenic, we performed whole-exome sequencing (WES) on two LNX-D1 46,XY subclones (LNX-D1B and LNX-D1T) and their parental pre-fusion cell line (LN-iPSC #1) to detect putative abnormalities at the nucleotide level. Variant calling was performing using hg19 as the reference genome. Among the selected variants, we detected only one (LNX-D1B) or two discrepancies (LNX-D1T) between the parental cell line and its 46,XY CT corrected clones at the level of all the autosomes. Conversely, 20% of variants on the www.moleculartherapy.org X chromosome were discordant, in agreement with the different origin of the donor and endogenous X chromosomes ( Figure 4B ). Taken together, these data confirm the CT event, also suggesting that the fusion process is not particularly damaging to the human genome.
DISCUSSION
In this study, we demonstrate for the first time that human iPSCs represent a suitable substrate for CT, paving the way for personalized medicine also for genomic disorders. Our data allow us to draw several conclusions in this regard. First, we have generated a donor cell line with a normal HSAX that could be used for the correction of iPSCs derived from any patient affected by X-linked "structural" disorders. Second, we have set up a high efficient retro-MMCT protocol for human iPSCs. Third, we observed that pluripotent cells acquiring an extra chromosome by MMCT are prone to spontaneously lose the additional one, probably due to abnormalities in nuclear morphology and decreased cellular fitness associated with trisomic aneuploidy, as recently reported. 24, 25 This loss has also been shown to occur in human triploid pluripotent cell lines. 25, 26 Any of the three sex chromosomes can be lost, since both XY and XX diploid clones were obtained, but only cells maintaining the normal (donor) X chromosome would survive selection; however, the specific loss of either endogenous X or Y chromosomes cannot be anticipated. Fourth, the CT method in itself is not mutagenic, although some mutations could arise during prolonged periods of culture, as occurs with any long term-cultured pluripotent stem cells. In the approach used in the present study, we first generated iPSCs from patient fibroblasts and subsequently performed MMCT. Alternatively, MMCT could be performed first in fibroblasts or other cells, followed by reprogramming to iPSCs. Although it is generally thought that MMCT is easier to perform in pluripotent stem cells than in primary fibroblasts, some authors have been successful with the second strategy. 27 In our opinion, both strategies are equivalent, since they use both the MMCT and the reprogramming steps, only changing their time sequence.
CT by MMCT could affect genome integrity, whose maintenance must be tested by whole-genome sequencing. A further limitation of the CT is linked to the epigenetic landscape of the transplanted chromosome, which could differ from the endogenous counterpart. This is particularly important in the case of the X chromosome, due to the phenomenon of X inactivation in corrected 46,XX cells. Although we did not investigate this point, we noticed that the exogenous chromosome was functional and was not inactivated, since the HPRT gene was obviously expressed to resist HAT selection.
The genetic defect of several diseases located on the X chromosome can be corrected by the CT approach. DMD, a severe muscle disease due to large deletions in about 80% of patients, looks like the most obvious candidate. Due to the large dystrophin gene size, spread on about 2 Mb of the X chromosome, and a transcript of more than 10 kb, classical gene therapy approaches have only partially been successful. More recently, results with subsets of mutations have been reported. 12, [28] [29] [30] In any case, the clinical improvement is modest, 31 and novel approaches are eagerly awaited. 32 Transfer of an HAC vector containing a complete dystrophin gene has also been shown to correct the DMD phenotype. 27, 33 However, HACs are sometimes silenced and/or are lost from the cells, 20 although other studies did show appropriate transgene maintenance and expression. 34, 35 Correction of mutations in DMD cells could be achieved by CT followed by differentiation to muscle cells and their injection in the muscles, an option that has been used by several researchers in muscle pathology. 27, 33, [36] [37] [38] The only needed additional step to the protocol used herein is the inactivation, before retro-MMCT fusion, of the HPRT gene on the endogenous X chromosome by CRISPR technology, allowing the use of HAT selection after retro-MMCT. We have recently shown the feasibility of this step by correcting the genetic defect in iPSCs from a mouse model of the X-linked CGD. Finally, this technique might not only lead to sex modification of pluripotent cells but also opens the way to the engineering of a synthetic human X chromosome, which could be modified ad libitum in a host cell line and subsequently introduced in normal pluripotent cells. 39 
MATERIALS AND METHODS

Ethics Approval and Consent to Participate
This study was approved by the Independent Ethics Committee of the Humanitas Clinical Institute (approval reference no. 2172).
Cell Cultures
Fibroblasts from the LN patient were obtained from the NIGMS Human Genetic Cell Repository at the Coriell Institute for Medical Research (GM 20394). Human dermal fibroblasts (HDFs) from a normal donor (Thermo Fisher Scientific, Waltham, MA, USA) and the LN fibroblasts were maintained in high-glucose DMEM medium, supplemented with 10% fetal bovine serum (FBS; Lonza, Basel, Switzerland).
The A9 mouse fibroblast line, Hprt À derivative of strain L (SigmaAldrich), 40 was grown in high-glucose DMEM (Lonza) supplemented with 10% FBS (Lonza). The A9/human hybrid cell line was obtained by whole-cell fusion between A9 cells and HDF cells; clones with a normal human X chromosome were selected in 1Â HAT medium (Sigma-Aldrich, Munich, Germany).
Hprt-defective CHO cells were kindly provided by Dr. E. Raimondi (University of Pavia, Pavia, Italy). The CHO cells were cultured in RPMI 1640 medium supplemented with 10% FBS (Lonza), and their microcell-fused derivative cells were selected in 1Â HAT medium (Sigma-Aldrich).
Human iPSCs were cultured in feeder-free conditions, using Essential 8 medium (Thermo Fisher Scientific) on human ESC (hESC)-qualified matrix Matrigel-coated six-well plates (BD Biosciences, San Jose, CA, USA) and their microcell-fused derivative cells were selected in HAT medium (Sigma-Aldrich).
Cell Reprogramming
Fibroblasts were reprogrammed by an overnight infection at an MOI of 1 in the presence of 4 ng/mL Polybrene (Sigma-Aldrich) with a third-generation lentiviral vector described by Mostoslavsky and colleagues, 21 carrying the Oct4, Sox2, and Klf4 reprogramming factors. The following day, the medium was replaced, and after 48 h cells were seeded onto mouse embryonic fibroblast (MEF) feeder layer with ES medium, which was changed daily. iPSC-like colonies were individually picked 4 weeks later, with a reprogramming efficiency of 0.01%. In the case of clone LNX-D, which was reprogrammed a second time after cell fusion, an integration-free CytoTune-iPS 2.0 Sendai reprogramming kit (Thermo Fisher Scientific), containing Sendai virus particles of the four Yamanaka factors, was used according to the manufacturer's instructions and cultured as specified above.
Generation of a CHO Cell Line Containing a Human Normal X Chromosome
To generate a CHO/HSAX cell line containing a HPRT + normal human chromosome, microcells from a hybrid A9 cell line containing a normal human X chromosome (A9/human), obtained by whole-cell fusion (WCF) between A9 cells and human dermal fibroblasts, were fused with Hprt À CHO cells according to standard procedures, and HAT-resistant clones were isolated. Cells were kept in RPMI 1640 supplemented with 10% FBS and 1Â HAT medium (SigmaAldrich).
MMCT
Classical MMCT was performed as previously described, with some modifications. 17, 22 After centrifugation at 160 Â g, 1 mL of a prewarmed solution of 50% PEG 1500 (Roche, Mannheim, Germany) was poured onto the cell pellet during 1 min, followed by extensive washing in serum-free RPMI 1640. 2.5 Â 10 6 iPSCs were plated in Matrigel in hESC-qualified matrix p60 dishes, and after 48 h 1Â HAT selection was added.
Retro-MMCT
For retro-MMCT, CHO/HSAX cells containing the normal human X chromosome were infected with the vesicular stomatitis virus G protein (VSV-G) pseudotyped lentiviral vector (MOI of 5) encoding EnvDR, essentially as previously described. 22 To analyze the efficiency of retro-MMCT, 5 Â 10 5 CHO/HSAX cells were plated on six gelatincoated high-speed polycarbonate centrifuge tubes (Nalgene, Rochester, NY, USA). On the next day, to promote micronuclei formation, the medium was changed to Colcemid medium (RPMI 1640 medium containing 20% FBS, penicillin/streptomycin, and 0.1 mg/mL Colcemid [KaryoMAX], Thermo Fisher Scientific). Microcells were prepared after 48 h (protocol A) or after 72 h (protocol B). After Colcemid incubation, the medium was replaced with DMEM medium containing latrunculin B 41 (0.2 mM; Enzo Life Sciences, Farmingdale, NY, USA), and the tubes were centrifuged at 16,000 Â g for 70 min at 37 C. The pellets containing extruded microcells were resuspended in 10 mL of serum-free RPMI 1640 and purified by two consecutive filtrations using membranes with 8-mm pores followed by one filtration using membranes with 5-mm pores (Millipore, Darmstadt, Germany). 
Chromosome Preparation and Analysis
Chromosome analysis was done on slide preparations of cells grown on coverslips. Briefly, cell cultures were treated with KaryoMAX Colcemid solution (Thermo Fisher Scientific) at a final concentration of 0.1 mg/mL for 2 h at 37 C. After hypotonic treatment with 0.075 M KCl and fixation in methanol/acetic acid (3:1 v/v), the slides were air-dried and mounted in Eukitt (Sigma-Aldrich). Chromosome counts and karyotype analyses were done on metaphases stained with Vectashield mounting medium with DAPI (Vector Laboratories, Burlingame, CA, USA) for G banding.
Images were captured using an Olympus BX61 research microscope equipped with a cooled CCD (charge-coupled device) camera and analyzed with Applied Imaging software CytoVision (CytoVision master system with mouse karyotyping). At least 10 karyotypes for each iPSC line were analyzed.
FISH
Green or orange whole-chromosome paint (WCP) specific for the human X chromosome (MetaSystems, Milan, Italy) and human genomic DNA were used as DNA probes. In situ hybridization was performed as previously described. 42 In brief, slides were treated with pepsin (0.004%) at 37 C for 30 s and dehydrated through the ethanol series before denaturation in 70% formamide/2Â SSC. The probes were denaturated at 80 C for 10 min and after a pre-annealing of 20 min at 37 C were applied on the slides. Hybridization was completed overnight at 37 C. Stringent washes were carried out in 0.4% SSC at 72 C for 5 min followed by 4% SSC/0.1% Tween 20 at room temperature (RT) for 5 min. Slides were mounted in Vectashield mounting medium with DAPI and then were scored under an Olympus BX61 research microscope equipped with a cooled CCD camera. Images were captured and analyzed with Applied Imaging software CytoVision (CytoVision master system with karyotyping and FISH).
EB Formation
Semi-confluent human iPSCs in one well of a six-well plate were dissociated by incubation with 2 mg/mL dispase (STEMCELL Technologies, Vancouver, BC, Canada) at 37 C for 2-3 min, or until the colonies began to lift off of the plate. The plates were gently shaken to help dislodge the colonies. The dispase solution was diluted in PBS and the suspension was transferred to a 15-mL centrifuge tube. The cell aggregates were allowed to settle by gravity, and the dispase solution was gently aspirated. The aggregates were washed three more times in PBS before being resuspended in 4 mL of Essential 6 medium supplemented with 5 mM Y-27632 ROCK inhibitor. The suspension was gently transferred to each well of a six-well ultra-low attachment plate (Corning Life Sciences, Acton, MA, USA). After 1 week in suspension, EBs were transferred to Matrigel-coated dishes and cultured in Essential 6 medium (Thermo Fisher Scientific) for an additional 2-3 weeks. Then, the cells were stained with antibodies against markers of all three embryonic germline layers and analyzed by immunofluorescence.
Immunofluorescence
For immunostaining, human iPSCs and EBs were fixed in 4% paraformaldehyde (PFA) for 10 min at room temperature, washed with PBS, and permeabilized in 0.3% Triton X-100 in PBS for 10 min at room temperature. Primary antibodies used were anti-Oct4 (ab18976, Abcam, Cambridge, UK), anti-Nanog (ab62734, Abcam), anti-SOX2 (ab97959, Abcam), anti-TRA-1-60 (ab16288, Abcam), anti-Nestin www.moleculartherapy.org (ab22035, Abcam), anti-a-SMA (ab5694, Abcam), anti-Brachyury (AF2085, R&D Systems, Minneapolis, MN, USA), and anti-GATA4 (ab134057, Abcam). After primary antibody incubation, samples were washed with PBS and incubated with secondary Alexa Fluor 488-conjugated antibodies (Life Technologies), diluted 1:2,000. Samples were also counterstained with DAPI (200 mg/mL). Slides were observed using an Olympus BX61 research microscope equipped with a cooled CCD camera. Images were captured and analyzed with Applied Imaging software CytoVision.
Sample Preparation and Genomic PCR Analysis
Genomic DNA was extracted from cell lines using a QIAamp DNA kit (QIAGEN, Hilden, Germany) according to the manufacturer's recommendations. Primer pairs for the analysis of WT HPRT allele and informative SNPs on the X chromosome are listed in Table S1 . PCRs were performed under the following conditions: initial denaturing for 5 min at 94 C; denaturing for 30 s at 94 C, 58 C for 30 s, extension for 30 s at 72 C, repeated 35 times; final extension for 5 min at 72 C. The PCR products were recovered using NucleoSpin gel and PCR Clean-up (Macherey-Nagel) and sequenced with specific primers.
WES and Analysis
WES was performed starting from 50 ng of genomic DNA using the Nextera Rapid Capture Exome Library kit (Illumina, San Diego, CA, USA) and the Illumina NextSeq500 platform, according to the manufacturers' instructions. Reads were aligned against the human reference genome (hg19) using BWA. 43 Variant calling was performed with GATK. 44 The analyzed target was restricted to the regions with an average coverage >30Â in the parental cell line sample. Variants found in the parental cell line, selected to have a minimum sequencing depth of 30x and a Phred Q score >30, were compared to the genotypes at the same genomic positions in the two corrected clones.
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